drugset / Trial / NCT00027898

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00027898

Phase 1 Completed 27 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of combining bortezomib with carboplatin and etoposide in treating patients who have advanced solid tumors that have not responded to previous treatment

Timeline

Start
2002-01
Primary completion
2006-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule Intravenous
Subject Carboplatin Small molecule Intravenous
Subject Etoposide Small molecule Intravenous